

Michel C Nussenzweig

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7464682/michel-c-nussenzweig-publications-by-citations.pdf>
Version: 2024-04-04

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

265 papers	41,399 citations	100 h-index	202 g-index
301 ext. papers	52,888 ext. citations	25.4 avg, IF	7.46 L-index

#	Paper	IF	Citations
265	Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. <i>Journal of Experimental Medicine</i> , 2001 , 194, 769-79	16.6	1501
264	Predominant autoantibody production by early human B cell precursors. <i>Science</i> , 2003 , 301, 1374-7	33.3	1483
263	Germinal centers. <i>Annual Review of Immunology</i> , 2012 , 30, 429-57	34.7	1346
262	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , 2020 , 584, 437-442	50.4	1167
261	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. <i>Science</i> , 2020 , 370,	33.3	1090
260	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <i>Science</i> , 2020 , 370,	33.3	994
259	Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. <i>Science</i> , 2011 , 333, 1633-7	33.3	874
258	Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. <i>Science</i> , 2010 , 329, 811-7	33.3	871
257	Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. <i>Cell</i> , 2010 , 143, 592-605	56.2	801
256	The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. <i>Nature</i> , 1995 , 375, 151-5	50.4	785
255	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. <i>ELife</i> , 2020 , 9,	8.9	784
254	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021 , 592, 616-622	50.4	730
253	Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. <i>Journal of Immunological Methods</i> , 2008 , 329, 112-24	2.5	702
252	Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. <i>Nature</i> , 2009 , 458, 636-40	50.4	695
251	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021 , 591, 639-644	50.4	652
250	SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. <i>Nature</i> , 2020 , 588, 682-687	50.4	651
249	Requirement for Ku80 in growth and immunoglobulin V(D)J recombination. <i>Nature</i> , 1996 , 382, 551-5	50.4	565

248	Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. <i>Nature</i> , 2015 , 522, 487-91	50.4	509
247	Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. <i>Nature</i> , 2013 , 503, 224-8	50.4	489
246	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , 2020 , 182, 828-842.e16	56.2	485
245	DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. <i>Nature</i> , 2000 , 404, 510-4	50.4	458
244	The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. <i>Journal of Cell Biology</i> , 2000 , 151, 673-84	7.3	444
243	AID is required to initiate Nbs1/gamma-H2AX focus formation and mutations at sites of class switching. <i>Nature</i> , 2001 , 414, 660-665	50.4	428
242	Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E3268-77	11.5	409
241	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. <i>Nature</i> , 2012 , 492, 118-22	50.4	401
240	Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. <i>Cell</i> , 2013 , 153, 126-38	56.2	376
239	Clonal selection in the germinal centre by regulated proliferation and hypermutation. <i>Nature</i> , 2014 , 509, 637-40	50.4	364
238	Autoreactivity in human IgG+ memory B cells. <i>Immunity</i> , 2007 , 26, 205-13	32.3	364
237	Antibodies in HIV-1 vaccine development and therapy. <i>Science</i> , 2013 , 341, 1199-204	33.3	361
236	Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. <i>Nature</i> , 2013 , 503, 277-80	50.4	359
235	Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. <i>Journal of Experimental Medicine</i> , 2012 , 209, 1153-65	16.6	356
234	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. <i>New England Journal of Medicine</i> , 2021 , 384, 2212-2218	59.2	347
233	Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. <i>Cell</i> , 2014 , 158, 1243-1253	56.2	338
232	AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. <i>Cell</i> , 2008 , 135, 1028-38	56.2	338
231	Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. <i>Nature</i> , 2010 , 467, 591-5	50.4	332

230	Increasing the potency and breadth of an HIV antibody by using structure-based rational design. <i>Science</i> , 2011 , 334, 1289-93	33.3	307
229	A Blueprint for HIV Vaccine Discovery. <i>Cell Host and Microbe</i> , 2012 , 12, 396-407	23.4	302
228	HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. <i>Nature</i> , 2016 , 535, 556-60	50.4	298
227	HIV-1 integration landscape during latent and active infection. <i>Cell</i> , 2015 , 160, 420-32	56.2	289
226	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	289
225	Translocation-capture sequencing reveals the extent and nature of chromosomal rearrangements in B lymphocytes. <i>Cell</i> , 2011 , 147, 95-106	56.2	286
224	Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. <i>Cell</i> , 2014 , 158, 989-999	56.2	283
223	Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. <i>Nature Medicine</i> , 2017 , 23, 185-191	50.5	282
222	The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. <i>Nature Immunology</i> , 2012 , 13, 1083-91	19.1	275
221	Structural insights on the role of antibodies in HIV-1 vaccine and therapy. <i>Cell</i> , 2014 , 156, 633-48	56.2	268
220	A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center. <i>Journal of Experimental Medicine</i> , 2011 , 208, 1243-52	16.6	263
219	Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. <i>Immunity</i> , 2013 , 39, 245-58	32.3	254
218	A robust pipeline for rapid production of versatile nanobody repertoires. <i>Nature Methods</i> , 2014 , 11, 1253-60	21.6	253
217	Combination therapy with anti-HIV-1 antibodies maintains viral suppression. <i>Nature</i> , 2018 , 561, 479-484	50.4	250
216	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , 2021 , 595, 426-431	50.4	247
215	Dynamic signaling by T follicular helper cells during germinal center B cell selection. <i>Science</i> , 2014 , 345, 1058-62	33.3	246
214	Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. <i>Journal of Experimental Medicine</i> , 2014 , 211, 2061-74	16.6	245
213	Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. <i>Blood</i> , 2012 , 120, 2240-8	2.2	242

212	Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. <i>Science</i> , 2016 , 352, 1001-4	33.3	240
211	HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. <i>Immunity</i> , 2016 , 45, 483-496	32.3	232
210	A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. <i>Nature</i> , 2016 , 533, 105-109	50.4	229
209	T follicular helper cell dynamics in germinal centers. <i>Science</i> , 2013 , 341, 673-7	33.3	226
208	Origin of chromosomal translocations in lymphoid cancer. <i>Cell</i> , 2010 , 141, 27-38	56.2	226
207	Role of BCR affinity in T cell dependent antibody responses in vivo. <i>Nature Immunology</i> , 2002 , 3, 570-5	19.1	226
206	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. <i>Cell</i> , 2015 , 161, 1280-92	56.2	219
205	AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. <i>Nature</i> , 2015 , 519, 87-91	50.4	211
204	HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 16538-43	11.5	208
203	The B-cell-specific transcription coactivator OCA-B/OBF-1/Bob-1 is essential for normal production of immunoglobulin isotypes. <i>Nature</i> , 1996 , 383, 542-7	50.4	208
202	T-independent type II immune responses generate memory B cells. <i>Journal of Experimental Medicine</i> , 2006 , 203, 305-10	16.6	204
201	Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice. <i>Cell</i> , 2016 , 166, 1445-1458.e12	56.2	204
200	HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. <i>Science</i> , 2016 , 352, 997-1001	33.3	202
199	AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. <i>Molecular Cell</i> , 2009 , 36, 631-41	17.6	201
198	Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. <i>Cell</i> , 2017 , 169, 597-609.e11	50.4	199
197	Antibody regulation of B cell development. <i>Nature Immunology</i> , 2000 , 1, 379-85	19.1	199
196	Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice. <i>Cell</i> , 2015 , 161, 1505-15	56.2	197
195	Role of antigen receptor affinity in T cell-independent antibody responses in vivo. <i>Nature Immunology</i> , 2002 , 3, 399-406	19.1	196

194	Somatic hypermutation is limited by CRM1-dependent nuclear export of activation-induced deaminase. <i>Journal of Experimental Medicine</i> , 2004 , 199, 1235-44	16.6	189
193	B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity. <i>Cell</i> , 2014 , 159, 1524-37	56.2	186
192	Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow. <i>Journal of Experimental Medicine</i> , 2015 , 212, 385-99	16.6	185
191	Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. <i>Cell Reports</i> , 2014 , 7, 785-95	10.6	180
190	Enhanced SARS-CoV-2 neutralization by dimeric IgA. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	178
189	Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability. <i>Cell</i> , 2014 , 159, 1538-48	56.2	176
188	A method for identification of HIV gp140 binding memory B cells in human blood. <i>Journal of Immunological Methods</i> , 2009 , 343, 65-7	2.5	171
187	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	171
186	Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 9727-32	11.5	169
185	Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E2083-90	11.5	168
184	Early antibody therapy can induce long-lasting immunity to SHIV. <i>Nature</i> , 2017 , 543, 559-563	50.4	162
183	Circulating precursors of human CD1c+ and CD141+ dendritic cells. <i>Journal of Experimental Medicine</i> , 2015 , 212, 401-13	16.6	154
182	Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. <i>Nature Structural and Molecular Biology</i> , 2016 , 23, 906-915	17.6	143
181	Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. <i>Nature Medicine</i> , 2018 , 24, 1701-1707	50.5	142
180	HUMORAL IMMUNITY. T cell help controls the speed of the cell cycle in germinal center B cells. <i>Science</i> , 2015 , 349, 643-6	33.3	137
179	Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. <i>Journal of Experimental Medicine</i> , 2012 , 209, 1469-79	16.6	131
178	Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. <i>Science</i> , 2021 , 371, 735-741	33.3	130
177	Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic. <i>Nature Medicine</i> , 2019 , 25, 547-553	50.5	126

176	Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2013 , 8, 79-103	34	125
175	Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. <i>Journal of Experimental Medicine</i> , 2013 , 210, 2813-21	16.6	121
174	V(D)J recombination: modulation of RAG1 and RAG2 cleavage activity on 12/23 substrates by whole cell extract and DNA-bending proteins. <i>Journal of Experimental Medicine</i> , 1997 , 185, 2025-32	16.6	121
173	Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E7908-E7916	11.5	117
172	Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. <i>Nature Communications</i> , 2016 , 7, 10618	17.4	117
171	The microanatomic segregation of selection by apoptosis in the germinal center. <i>Science</i> , 2017 , 358,	33.3	114
170	A monoclonal antibody to the DEC-205 endocytosis receptor on human dendritic cells. <i>Human Immunology</i> , 2000 , 61, 729-38	2.3	106
169	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , 2021 , 12, 4196	17.4	106
168	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. <i>PLoS Pathogens</i> , 2016 , 12, e1005520	7.6	106
167	Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. <i>Cell</i> , 2016 , 165, 1609-1620	56.2	103
166	Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. <i>Journal of Virology</i> , 2015 , 89, 2659-71	6.6	101
165	Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. <i>Journal of Experimental Medicine</i> , 2017 , 214, 2573-2590	16.6	100
164	Circulating human B cells that express surrogate light chains and edited receptors. <i>Nature Immunology</i> , 2000 , 1, 207-13	19.1	100
163	Plasmodium Infection Promotes Genomic Instability and AID-Dependent B Cell Lymphoma. <i>Cell</i> , 2015 , 162, 727-37	56.2	98
162	Development and migration of plasma cells in the mouse lymph node. <i>Immunity</i> , 2010 , 33, 118-27	32.3	98
161	Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	96
160	Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques. <i>Nature</i> , 2019 , 570, 468-473	50.4	95
159	Progress toward active or passive HIV-1 vaccination. <i>Journal of Experimental Medicine</i> , 2017 , 214, 3-16	16.6	94

158	Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo. <i>Cell</i> , 2017 , 170, 637-648.e10	56.2	93
157	Plasma Neutralization of the SARS-CoV-2 Omicron Variant.. <i>New England Journal of Medicine</i> , 2021 ,	59.2	93
156	Autoantibodies neutralizing type I IFNs are present in 4% of uninfected individuals over 70 years old and account for 20% of COVID-19 deaths. <i>Science Immunology</i> , 2021 , 6,	28	91
155	Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. <i>PLoS ONE</i> , 2011 , 6, e24078	3.7	88
154	Human dendritic cells (DCs) are derived from distinct circulating precursors that are precommitted to become CD1c+ or CD141+ DCs. <i>Journal of Experimental Medicine</i> , 2016 , 213, 2861-2870	16.6	87
153	Collecting lymphatic vessel permeability facilitates adipose tissue inflammation and distribution of antigen to lymph node-homing adipose tissue dendritic cells. <i>Journal of Immunology</i> , 2015 , 194, 5200-1053	5.3	84
152	Intra-spike crosslinking overcomes antibody evasion by HIV-1. <i>Cell</i> , 2015 , 160, 433-46	56.2	84
151	Sequencing and cloning of antigen-specific antibodies from mouse memory B cells. <i>Nature Protocols</i> , 2016 , 11, 1908-1923	18.8	83
150	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , 2021 , 54, 1853-1868.e7	32.3	83
149	Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 10598-603	11.5	82
148	Absence of MHC class II on cDCs results in microbial-dependent intestinal inflammation. <i>Journal of Experimental Medicine</i> , 2016 , 213, 517-34	16.6	81
147	Polyreactive antibodies in adaptive immune responses to viruses. <i>Cellular and Molecular Life Sciences</i> , 2012 , 69, 1435-45	10.3	81
146	Independent Roles of Switching and Hypermutation in the Development and Persistence of B Lymphocyte Memory. <i>Immunity</i> , 2016 , 44, 769-81	32.3	79
145	Orientation-specific joining of AID-initiated DNA breaks promotes antibody class switching. <i>Nature</i> , 2015 , 525, 134-139	50.4	76
144	Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. <i>Journal of Experimental Medicine</i> , 2013 , 210, 1235-49	16.6	76
143	Germinal center reutilization by newly activated B cells. <i>Journal of Experimental Medicine</i> , 2009 , 206, 2907-14	16.6	76
142	Clonal CD4 T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation. <i>Nature Medicine</i> , 2018 , 24, 604-609	50.5	72
141	A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. <i>Nature Medicine</i> , 2018 , 24, 610-616	50.5	71

140	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , 2021 ,	50.4	69
139	Classical Flt3L-dependent dendritic cells control immunity to protein vaccine. <i>Journal of Experimental Medicine</i> , 2014 , 211, 1875-91	16.6	68
138	Disruption of an antimycobacterial circuit between dendritic and helper T cells in human SPPL2a deficiency. <i>Nature Immunology</i> , 2018 , 19, 973-985	19.1	67
137	Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. <i>Journal of Experimental Medicine</i> , 2014 , 211, 2361-72	16.6	67
136	A mouse model for HIV-1 entry. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 15859-64	11.5	67
135	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. <i>Nature</i> , 2021 ,	50.4	65
134	Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. <i>Nature Communications</i> , 2015 , 6, 8167	17.4	62
133	Secondary V(D)J recombination in B-1 cells. <i>Nature</i> , 1999 , 397, 355-9	50.4	62
132	Differential regulation of self-reactivity discriminates between IgG+ human circulating memory B cells and bone marrow plasma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 18044-8	11.5	61
131	Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals 2020 ,		60
130	Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell Fates. <i>Cell</i> , 2020 , 183, 1298-1311.e11	56.2	59
129	Persistent cellular immunity to SARS-CoV-2 infection. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	59
128	Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. <i>Nature Communications</i> , 2018 , 9, 1251	17.4	58
127	L-Myc expression by dendritic cells is required for optimal T-cell priming. <i>Nature</i> , 2014 , 507, 243-7	50.4	58
126	Protein Amounts of the MYC Transcription Factor Determine Germinal Center B Cell Division Capacity. <i>Immunity</i> , 2019 , 51, 324-336.e5	32.3	56
125	Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy. <i>New England Journal of Medicine</i> , 2016 , 375, 2019-2021	59.2	55
124	Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. <i>Journal of Experimental Medicine</i> , 2018 , 215, 2311-2324	16.6	55
123	Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. <i>Journal of Virology</i> , 2013 , 87, 10047-58	6.6	54

122	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York 2021 ,		54
121	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants 2021 ,		54
120	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. <i>Immunity</i> , 2019 , 50, 1513-1529.e9	32.3	53
119	Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 4743-4748	11.5	53
118	Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. <i>Journal of Experimental Medicine</i> , 2010 , 207, 1995-2002	16.6	53
117	Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion. <i>Cell Host and Microbe</i> , 2018 , 24, 579-592.e4	23.4	51
116	Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2016 , 126, 415-23	15.9	50
115	Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. <i>Nature Medicine</i> , 2020 , 26, 222-227	50.5	50
114	Enhanced HIV-1 neutralization by antibody heterologation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 875-80	11.5	49
113	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. <i>Nature</i> , 2021 , 595, 278-282	50.4	49
112	Structural basis for germline antibody recognition of HIV-1 immunogens. <i>ELife</i> , 2016 , 5,	8.9	48
111	Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. <i>Journal of Virology</i> , 2010 , 84, 5032-42	6.6	46
110	ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens. <i>Cell Reports Medicine</i> , 2020 , 1, 100123	18	46
109	Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 6049-54	11.5	45
108	Defining human dendritic cell progenitors by multiparametric flow cytometry. <i>Nature Protocols</i> , 2015 , 10, 1407-22	18.8	44
107	Antigen delivery to CD11c+CD8- dendritic cells induces protective immune responses against experimental melanoma in mice in vivo. <i>Journal of Immunology</i> , 2014 , 192, 5830-8	5.3	43
106	Evolution of Antibody Immunity to SARS-CoV-2 2021 ,		43
105	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. <i>Nature Medicine</i> , 2020 , 26, 1339-1350	50.5	43

104	A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates. <i>Cell Reports</i> , 2018 , 25, 1385-1394.e7	10.6	43
103	Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. <i>PLoS Pathogens</i> , 2018 , 14, e1006860	7.6	42
102	Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir. <i>Journal of Experimental Medicine</i> , 2019 , 216, 2253-2264	16.6	42
101	Relationship between intact HIV-1 proviruses in circulating CD4 T cells and rebound viruses emerging during treatment interruption. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E11341-E11348	11.5	42
100	The cell cycle restricts activation-induced cytidine deaminase activity to early G1. <i>Journal of Experimental Medicine</i> , 2017 , 214, 49-58	16.6	39
99	Inducible targeting of cDCs and their subsets in vivo. <i>Journal of Immunological Methods</i> , 2016 , 434, 32-8	2.5	38
98	Epigenetic targeting of activation-induced cytidine deaminase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 18667-72	11.5	37
97	Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies. <i>ELife</i> , 2017 , 6,	8.9	37
96	HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells. <i>Journal of Experimental Medicine</i> , 2019 , 216, 1301-1310	16.6	36
95	A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. <i>PLoS Pathogens</i> , 2015 , 11, e1005238	7.6	36
94	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. <i>Nature</i> , 2021 , 593, 424-428	50.4	36
93	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses 2020 ,		35
92	Antigen-responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	34
91	Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. <i>PLoS ONE</i> , 2019 , 14, e0219142	3.7	33
90	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants 2020 ,		32
89	Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. <i>Journal of Virology</i> , 2018 , 92,	6.6	32
88	Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption. <i>Journal of Virology</i> , 2019 , 93,	6.6	31
87	Plasma neutralization properties of the SARS-CoV-2 Omicron variant. 2021 ,		31

86	Author response: Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants 2020 ,		31
85	An inherited immunoglobulin class-switch recombination deficiency associated with a defect in the INO80 chromatin remodeling complex. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 135, 998-1007.e6	11.5	30
84	Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies 2020 ,		30
83	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. <i>Nature Communications</i> , 2021 , 12, 4886	17.4	30
82	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. <i>Cell Reports</i> , 2021 , 36, 109760	10.6	29
81	Risk of Zika microcephaly correlates with features of maternal antibodies. <i>Journal of Experimental Medicine</i> , 2019 , 216, 2302-2315	16.6	28
80	Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies 2021 ,		27
79	Clonal analysis of human dendritic cell progenitor using a stromal cell culture. <i>Journal of Immunological Methods</i> , 2015 , 425, 21-26	2.5	25
78	A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. <i>Cell Host and Microbe</i> , 2020 , 28, 335-349.e6	23.4	25
77	Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies 2021 ,		24
76	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. <i>Cell Reports</i> , 2021 , 36, 109450	10.6	23
75	Translocation capture sequencing: a method for high throughput mapping of chromosomal rearrangements. <i>Journal of Immunological Methods</i> , 2012 , 375, 176-81	2.5	21
74	Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection 2020 ,		21
73	Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. <i>Journal of Virology</i> , 2013 , 87, 8535-44	6.6	20
72	Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas. <i>MBio</i> , 2015 , 6,	7.8	19
71	OcaB regulates transitional B cell selection. <i>International Immunology</i> , 2003 , 15, 1099-104	4.9	19
70	Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year 2021 ,		19
69	Dynamic regulation of T selection during the germinal centre reaction. <i>Nature</i> , 2021 , 591, 458-463	50.4	19

68	Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. <i>Journal of Virology</i> , 2020 , 94,	6.6	18
67	Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies 2020 ,		18
66	Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro 2020 ,		15
65	The Chromatin Reader ZMYND8 Regulates Igh Enhancers to Promote Immunoglobulin Class Switch Recombination. <i>Molecular Cell</i> , 2018 , 72, 636-649.e8	17.6	15
64	Germinal Centers.. <i>Annual Review of Immunology</i> , 2022 ,	34.7	14
63	Germinal center-dependent and -independent memory B cells produced throughout the immune response. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	14
62	Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	14
61	Increased Memory B Cell Potency and Breadth After a SARS-CoV-2 mRNA Boost.. <i>Nature</i> , 2022 ,	50.4	14
60	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies 2021 ,		13
59	Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses. <i>Journal of Experimental Medicine</i> , 2019 , 216, 2316-2330	16.6	12
58	Isolation of single HIV-1 Envelope specific B cells and antibody cloning from immunized rhesus macaques. <i>Journal of Immunological Methods</i> , 2020 , 478, 112734	2.5	12
57	A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 7981-7989	11.5	11
56	Nanoparticles presenting clusters of CD4 expose a universal vulnerability of HIV-1 by mimicking target cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 18719-18728	11.5	11
55	Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates. <i>Journal of Virology</i> , 2020 ,	6.6	11
54	Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. <i>Journal of Virology</i> , 2021 , 95,	6.6	11
53	RAG1/2 induces genomic insertions by mobilizing DNA into RAG1/2-independent breaks. <i>Journal of Experimental Medicine</i> , 2017 , 214, 815-831	16.6	10
52	Identification of chromosomal translocation hotspots via scan statistics. <i>Bioinformatics</i> , 2014 , 30, 2551-87.2		10
51	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.. <i>Immunity</i> , 2022 ,	32.3	10

50	Persistent Cellular Immunity to SARS-CoV-2 Infection 2020 ,		9
49	Immunotherapy during the acute SHIV infection of macaques confers long-term suppression of viremia. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	9
48	Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160(BaL.). <i>Journal of Immunological Methods</i> , 2013 , 397, 47-54	2.5	8
47	Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants 2021 ,		8
46	A humanized mouse model of chronic COVID-19.. <i>Nature Biotechnology</i> , 2021 ,	44.5	8
45	Ralph Steinman (1943-2011). <i>Nature</i> , 2011 , 478, 460	50.4	7
44	Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination		7
43	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. <i>PLoS Pathogens</i> , 2021 , 17, e1009688	7.6	7
42	High genetic barrier to escape from human polyclonal SARS-CoV-2 neutralizing antibodies		7
41	Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies. <i>Nature Communications</i> , 2020 , 11, 3195	17.4	6
40	A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch. <i>ELife</i> , 2020 , 9,	8.9	6
39	Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	6
38	Amplification of highly mutated human Ig lambda light chains from an HIV-1 infected patient. <i>Journal of Immunological Methods</i> , 2015 , 418, 61-5	2.5	5
37	An apoptosis-dependent checkpoint for autoimmunity in memory B and plasma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 24957-24963	11.5	5
36	A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls. <i>EBioMedicine</i> , 2021 , 65, 103252	8.8	5
35	TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. <i>Clinical Chemistry</i> , 2021 , 67, 1249-1258	5.5	5
34	Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 9865-9875	11.5	5
33	Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice 2021 ,		5

32	Redemption for self-reactive antibodies. <i>Science</i> , 2018 , 360, 152-153	33.3	4
31	Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. <i>Science Translational Medicine</i> , 2021 , 13, eabk1533	17.5	4
30	Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice 2021 ,		4
29	Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation. <i>Cell Reports</i> , 2021 , 37, 109942	10.6	3
28	Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence. <i>Journal of Experimental Medicine</i> , 2021 , 218,	16.6	3
27	Antigen responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir		3
26	Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration. <i>Antibodies</i> , 2020 , 9,	7	3
25	Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus. <i>Aids</i> , 2021 , 35, 1567-1574	3.5	3
24	Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose. 2022 ,		3
23	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2200413119 ^{11.5}	11.5	3
22	HIV: Persistence through division. <i>Journal of Experimental Medicine</i> , 2017 , 214, 875-876	16.6	2
21	A New Way to Diversify Antibodies by DNA Transposition. <i>Cell</i> , 2016 , 164, 601-2	56.2	2
20	Engineering Antibodies to Enhance Activity and Increase Half-life. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A210-A210	1.6	2
19	Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.. <i>Lancet Microbe, The</i> , 2022 , 3, e203-e214	22.2	2
18	Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against primary African isolates		2
17	Bispecific antibody neutralizes circulating SARS-CoV-2 variants, prevents escape and protects mice from disease 2021 ,		2
16	TOP-Plus is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability 2021 ,		2
15	Single-Cell Sorting of HBsAg-Binding Memory B Cells from Human Peripheral Blood Mononuclear Cells and Antibody Cloning. <i>STAR Protocols</i> , 2020 , 1, 100129	1.4	1

14	Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119,	11.5	1
13	Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins. 2022 ,		1
12	Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer.. <i>Nature Communications</i> , 2022 , 13, 732	17.4	1
11	Analysis of HIV-1 latent reservoir and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117		1
10	Characterization of intact proviruses in blood and lymph node from HIV-infected individuals undergoing analytical treatment interruption		1
9	A humanized mouse model of chronic COVID-19 to evaluate disease mechanisms and treatment options 2021 ,		1
8	Sequencing, cloning, and antigen binding analysis of monoclonal antibodies isolated from single mouse B cells. <i>STAR Protocols</i> , 2021 , 2, 100389	1.4	1
7	JEM Advisory Editorial Board: Increasing diversity. <i>Journal of Experimental Medicine</i> , 2017 , 214, 2169	16.6	o
6	Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope. <i>Npj Vaccines</i> , 2021 , 6, 126	9.5	o
5	The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.. <i>Trials</i> , 2022 , 23, 263	2.8	o
4	Editorial Board: Expanding on the basis of cancer. <i>Journal of Experimental Medicine</i> , 2019 , 216, 1725	16.6	
3	The new face of JEM. <i>Journal of Experimental Medicine</i> , 2017 , 214, 3467	16.6	
2	Adaptation of HIV-1 Envelope Glycoprotein gp120 to Humoral Immunity over the Course of the Epidemic. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, A224-A224	1.6	
1	Immunoglobulins and B cell development. <i>Biochemical Society Transactions</i> , 2000 , 28, A487-A487	5.1	